Literature DB >> 26714579

Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent.

Hillel Sternlicht1, George L Bakris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26714579     DOI： 10.1038/nrneph.2015.217

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

Review 1.  Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.

Authors:  Raymond V Oliva; George L Bakris
Journal:  J Am Soc Hypertens       Date:  2014-02-12

Review 2.  Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.

Authors:  William L Baker; Lindsay R Smyth; Daniel M Riche; Emily M Bourret; Kevin W Chamberlin; William B White
Journal:  J Am Soc Hypertens       Date:  2014-01-26

3.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

Authors:  Caroline Bonner; Julie Kerr-Conte; Valéry Gmyr; Gurvan Queniat; Ericka Moerman; Julien Thévenet; Cédric Beaucamps; Nathalie Delalleau; Iuliana Popescu; Willy J Malaisse; Abdullah Sener; Benoit Deprez; Amar Abderrahmani; Bart Staels; François Pattou
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

5.  Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Michael A Weber; Traci A Mansfield; Valerie A Cain; Nayyar Iqbal; Shamik Parikh; Agata Ptaszynska
Journal:  Lancet Diabetes Endocrinol       Date:  2015-11-27       Impact factor: 32.069

6.  Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Authors:  Ilkka Tikkanen; Kirsi Narko; Cordula Zeller; Alexandra Green; Afshin Salsali; Uli C Broedl; Hans J Woerle
Journal:  Diabetes Care       Date:  2014-09-30       Impact factor: 19.112

7.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

8.  Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.

Authors:  George L Bakris; Malini Iyengar; Mary Ann Lukas; Paul Ordronneau; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-07-08       Impact factor: 3.738

9.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

Authors:  H J Lambers Heerspink; D de Zeeuw; L Wie; B Leslie; J List
Journal:  Diabetes Obes Metab       Date:  2013-06-05       Impact factor: 6.577
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.